2001-09 to 2004-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2011-09 to Present - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - Researcher
2006-06 to 2011-08 - Van Andel Research Institute, USA - Postdoctoral Researcher
2004-08 to 2006-05 - Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Postdoctoral Researcher
Prostate Cancer Foundation, 2017 PCF Challenge Award
Guangdong Provincial Science and Technology Award, Second Prize, Provincial Level, 2018
Research
Drug Chemistry Computer-Aided Drug Design Structural Biology Nuclear Receptor Drugs Epigenetics
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity, Corresponding Author, 2024
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia, Corresponding Author, 2024
Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo4,5-cquinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation, Corresponding Author, 2024
1,3-disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells, Corresponding Author, 2024
Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia, Corresponding Author, 2024
Discovery and pharmacological characterization of 1,2,3,4-tetrahydroquinoline derivatives as RORγ inverse agonists against prostate cancer, Corresponding Author, 2024
Advances in Anti-prostate Cancer-Related Nuclear Receptors and Small Molecule Drugs, Corresponding Author, 2023
Rational design, synthesis and biological evaluation of benzodisoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer, Corresponding Author, 2023
Discovery of a Highly Selective and H435R-Sensitive ThyroidHormone Receptor?Agonist, Corresponding Author, 2022
Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain, Corresponding Author, 2022
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer, Corresponding Author, 2022
Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders, 7th Author, 2022
Structure-Based Discovery and Optimization of Furo3,2-cpyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors, Corresponding Author, 2022
Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors, Corresponding Author, 2022
Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors, Corresponding Author, 2022
Design,synthesis and pharmacological characterization of N-(3-ethylbenzodisoxazol-5-yl)sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia, Corresponding Author, 2022
Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors, Corresponding Author, 2022
Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist, Corresponding Author, 2021
The natural compound rutaecarpine promotes white adipocyte browning through activation of the AMPK-PRDM16 axis, 10th Author, 2021
Pyrido2, 3-dpyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors, 11th Author, 2021
Y06014 is a selective BET inhibitor for the treatment of prostate cancer, Corresponding Author, 2021
e-Graphene: A Computational Platform for the Prediction of Graphene-Based Drug Delivery System by Quantum Genetic Algorithm and Cascade Protocol, 5th Author, 2021
Design and Optimization of 3 '-(Imidazo1,2-alphapyrazin-3-yl)-1,1 '-biphenyl-3-carboxamides as Selective DDR1 Inhibitors, 8th Author, 2020
Quantitative Prediction of Hemolytic Toxicity for Small Molecules and Their Potential Hemolytic Fragments by Machine Learning and Recursive Fragmentation Methods, 5th Author, 2020
In Silico Prediction of Hemolytic Toxicity on the Human Erythrocytes for Small Molecules by Machine-Learning and Genetic Algorithm, 6th Author, 2020
Discovery and optimization of novel N-benzyl-3,6-dimethylbenzodisoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities, Corresponding Author, 2020
e-Sweet: A Machine-Learning Based Platform for the Prediction of Sweetener and Its Relative Sweetness, 4th Author, 2019
Prediction of Hemolytic Toxicity for Saponins by Machine-Learning Methods, 5th Author, 2019
Identification of New Small Molecule Inducers of Estrogen-related Receptor alpha (ERR alpha) Degradation, 9th Author, 2019
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer, Corresponding Author, 2019
Computational Prediction of a New ADMET Endpoint for Small Molecules: Anticommensal Effect on Human Gut Microbiota, 5th Author, 2019
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR gamma Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer, Corresponding Author, 2019
Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist, Corresponding Author, 2019
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer, Corresponding Author, 2018
Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer, Corresponding Author, 2018
Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin, 8th Author, 2018
e-Bitter: Bitterant Prediction by the Consensus Voting From the Machine-Learning Methods, 6th Author, 2018
The natural compound, formononetin, extracted from Astragalus membranaceus increases adipocyte thermogenesis by modulating PPAR gamma activity, 16th Author, 2018
Structure-Based Discovery and Optimization of Benzo&ITd&ITisoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC), Corresponding Author, 2018
Y08060: A Selective BET Inhibitor for Treatment ofProstate Cancer, Corresponding Author, 2018
Design, synthesis, and structure-activity relationship study of 2-oxo-3,4-dihydropyrimido4,5-dpyrimidines as new colony stimulating factor 1 receptor (csf1r) kinase inhibitors, 9th Author, 2018
The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine, 8th Author, 2018
A structure-guided optimization of pyrido2,3-dpyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties, 7th Author, 2017
Proposed Hydrogen-Bonding Index of Donor or Acceptor Reflecting Its Intrinsic Contribution to Hydrogen-Bonding Strength, 7th Author, 2017
2-Aminopyrimidine Derivatives as New SelectiveFibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors, 7th Author, 2017
Structural basis for functional selectivity and ligand recognition revealed by crystal structures of human secreted phospholipase A2 group IIE., 5th Author, 2017
Visualization and Quantification of Browning Using a Ucp1-2A-Luciferase Knock-in Mouse Model., 8th Author, 2017
Keywords
Drug ChemistryComputer-Aided Drug DesignStructural BiologyNuclear Receptor DrugsEpigeneticsPharmacologyCancer ResearchMolecular DesignSynthesisBiomedicine
Area of Focus
Anti-Tumor | Small Molecule | Drug Development | Cancer | Chemistry | Pharmacology | Biomedicine | Oncology | Medicinal Chemistry | Therapeutics
